Brincidofovir oral SU

The Defense Logistics Agency Troop Support Medical Supply Chain seeks quotes for two bottles (BT) of brincidofovir oral suspension, NSN 6505-01-735-0149, under request for quotation SPE2DP27T0212, with quotes due November 9, 2026. No set-aside is used, and quotes must be submitted through DIBBS.

Delivery is required within 20 days to Walter Reed National Military Medical Center, Building 54, Bethesda, Maryland, on a FOB Destination basis with inspection at destination. The product is identified as TEMBEXA, manufactured by Emergent Biodefense Operations Lansing, and is a commercial pharmaceutical regulated by the FDA. The item carries a non-extendable 60-month shelf-life requirement and must comply with Medical Marking Standard No. 1 and MIL-STD-129 marking standards. Key compliance provisions include DFARS 252.225-7001 (Buy American Act), FAR 52.246-2, and prohibitions on covered telecommunications equipment and additive manufacturing. The apparently successful offeror must submit a hazard warning label and Material Safety Data Sheet before award if materials contain substances regulated under the Hazard Communication Standard. Quoters are encouraged to submit quantity ranges to facilitate potential requirement adjustments, and micro-purchase awards may be made before the return date. The solicitation uses Fast Auto Evaluation, and the source states no evaluation weighting.